HUTCHMED
Completion of enrolment in amidizalisib China Phase II registration trial in FLHUTCHMED
Completion of enrolment of China Phase III ESLIM-01 trial of sovleplenib in primary ITPHUTCHMED
Initiation of China Phase II/III of fruquintinib+ sintilimab for advanced RCC